绥美凯该如何使用？

(Dolutea Paramid Tablets) is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Retail price 2880$/month. Suimeike (dolute abalamib tablets) is a medicine containing three active ingredients, used to treat HIV infection in adults and children over 12 years of age weighing more than 40 kilograms. Trimax (dolutegravir) contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs).

Dolutegravir: Can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Abacavir: Abacavir is a carbocyclic synthetic nucleoside analog. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP) under the action of intracellular enzymes, which is a deoxyguanosine-5'-triphosphate (dGTP) analog. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Lamivudine: Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

For adults and adolescents, the recommended dose of Trimax is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative.

Trimax should not be used on individuals who carry the HLA-B5701 gene. Patients who carry this gene are at high risk of developing severe hypersensitivity reactions (type I allergic reactions) when using Trimax. Therefore, before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B5701" gene.

The most common symptoms of a hypersensitivity reaction are: fever (high fever) and rash. Other common reactions include: nausea (feeling like you are throwing up), vomiting, diarrhea, abdominal pain, and tiredness. May also include: joint or muscle pain, neck swelling, shortness of breath, sore throat, cough, occasional headache, eye inflammation (conjunctivitis), mouth sores, low blood pressure, and numbness in the hands and feet. Hypersensitivity reactions can occur at any time during treatment with Trimax, but are more common during the first 6 weeks of treatment.

Please contact your doctor immediately if the following symptoms occur when patients take (Doteta abalamib Tablets): rash; fever; shortness of breath, sore throat, cough; nausea or vomiting, diarrhea, abdominal pain; severe tiredness or pain.